✦ LIBER ✦

Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance

✍ Scribed by Djuana M. E. Harvell; Nicole S. Spoelstra; Meenakshi Singh; James L. McManaman; Christina Finlayson; Tzu Phang; Susan Trapp; Lawrence Hunter; Wendy W. Dye; Virginia F. Borges; Anthony Elias; Kathryn B. Horwitz; Jennifer K. Richer

Book ID: 106378073
Publisher: Springer US
Year: 2008
Tongue: English
Weight: 689 KB
Volume: 112
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-008-9897-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Neoadjuvant systemic therapy for ER+ bre

Neoadjuvant systemic therapy for ER+ breast cancer: Is it safe to assess therapy responses based on immunohistochemical assessment of molecular sub-typing?

✍ Hussain, Tasadooq; Grover, Kartikaye; Mahapatra, Tapan; McManus, Penelope; Dhadd 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 50 KB

0174 A phase III study of adjuvant endoc

0174 A phase III study of adjuvant endocrine therapy with or without chemotherapy for postmenopausal breast cancer patients who responded to neoadjuvant letrozole: Study design of the new primary endocrine-therapy origination study [NEOS (N-SAS BC06)]

✍ H. Iwata; N. Masuda; T. Toyama; N. Taira; Y. Yamamoto; S. Saji; M. Kashiwaba; T. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB